North America Interventional Cardiology Stents Market - 2025-2033

North America Interventional Cardiology Stents Market Size

The North America interventional cardiology stents market size reached US$ 1.96 billion in 2024 and is expected to reach US$ 3.57 billion by 2033, growing at a CAGR of 6.9% during the forecast period 2025-2033.

North America Interventional Cardiology Stents Market Overview

Interventional cardiology stents are small devices used in minimally invasive procedures to treat coronary artery disease. By acting as a mechanical scaffold, stents help maintain the patency of blood vessels, ensuring adequate blood flow to the heart. There are various types of stents, with drug-eluting stents being the most commonly used due to their ability to prevent the artery from re-narrowing. While the procedure is effective in treating heart disease and preventing heart attacks, it carries certain risks, which are minimized with proper medication and follow-up care.

The key market players are Medtronic, Terumo Corporation, Boston Scientific Corporation, Abbott, Johnson & Johnson Services, Inc., and Cook Medical, which are the North America leaders. These companies are actively involved in developing advanced stents by acquiring regulatory approvals in interventional cardiology.

The current market growth is propelled by the recent product launches by the major market leaders. For instance, in May 2024, Abbott launched the XIENCE Sierra Everolimus (drug) Eluting Coronary Stent System in India. XIENCE Sierra is one of the latest generation stents in the XIENCE family, now available to people suffering from blocked coronary arteries. For interventional cardiologists, it brings unparalleled safety to the most complex cases.

North America Interventional Cardiology Stents Market Dynamics: Drivers & Restraints

Shift towards bioresorbable stents is significantly driving the market growth

The shift towards bioresorbable stents is significantly driving the growth of the North America interventional cardiology stents market due to their potential benefits over traditional drug-eluting stents (DES). These stents offer a temporary support structure that dissolves over time, eliminating the need for permanent metallic implants and addressing some of the long-term issues associated with DES.

For instance, in July 2024, MicroPort Scientific Corporation announced that its wholly-owned subsidiary, Shanghai MicroPort Medical (Group) Co., Ltd., received market approval from the National Medical Products Administration (NMPA) for Firesorb, the world's first next-generation fully bioresorbable cardiac stent.

Bioresorbable stents, such as Abbott’s Absorb and Boston Scientific’s Synergy, provide temporary support to the vessel wall while allowing natural healing processes to occur. These stents eventually dissolve within 2 to 3 years, leaving no foreign material behind and allowing the vessel to return to its natural function. Advances in polymer technology and device design have led to the development of newer generations of bioresorbable stents, which are safer and more effective.

Procedural risks and complications are hampering the market growth

The presence of procedural risks and complications is expected to hamper the growth of the interventional cardiology stents market by affecting patient outcomes, increasing healthcare costs, and limiting the widespread adoption of advanced techniques. These risks can lead to complications such as myocardial infarction, stroke, restenosis, and the need for repeat procedures, ultimately impacting patient safety and the economic viability of treatments.

Despite advancements in interventional cardiology stents, procedures still carry significant risks. Complications such as myocardial infarction (heart attack), stroke, and arrhythmias can occur during and after interventions like percutaneous coronary interventions (PCI) or stent placements. These complications not only affect patient health but also contribute to higher mortality rates.

According to the study by the Journal of the Society for Cardiovascular Angiography & Interventions, even among emergency patients, the hospital mortality rate after PCI was 3.9%, and the total 30-day mortality was 4.9%. Restenosis is a frequent concern with procedures involving stents, especially drug-eluting stents (DES). According to ScienceDirect, the reported incidence of restenosis varies between 15% and 55%, with most studies averaging around 30%.

North America Interventional Cardiology Stents Market Segment Analysis

The North America interventional cardiology stents market is segmented based on product type and end-user.

Product Type:

The drug-eluting stents segment holds 82.78% in the North America interventional cardiology stents market

Drug-eluting stents (DES) are designed to release drugs that prevent the artery from narrowing again (restenosis) after the stent is placed. This reduces the need for repeat procedures and is one of the primary reasons for their widespread adoption. For instance, the Xience Prime DES from Abbott has been shown to dramatically lower restenosis rates compared to bare-metal stents. As restenosis is a major concern in coronary artery disease treatment, the ability of DES to reduce these rates has driven their widespread use in PCI (Percutaneous Coronary Intervention) procedures.

DES offers better long-term results, with fewer cases of stent thrombosis and recurrent myocardial infarctions (heart attacks). This is due to the drug coating that helps prevent the excessive growth of tissue within the artery, leading to safer and more durable interventions. The product launches from major companies further boost the market growth. For instance, in December 2023, Terumo India launched Ultimaster Nagomi, a drug-eluting stent for treating coronary artery disease, a move to invest in newer generation stents to improve the safety and effectiveness of coronary artery treatments.

Due to their effectiveness in preventing restenosis and reducing the need for repeat procedures, DES have gained preference among both patients and healthcare providers. Patients are more likely to choose DES over bare-metal stents due to the reduced risk of restenosis and the possibility of a better quality of life post-procedure.

North America Interventional Cardiology Stents Market Competitive Landscape

Top companies in the North America interventional cardiology stents market include Medtronic, Terumo Corporation, Boston Scientific Corporation, Abbott, Johnson & Johnson Services, Inc., and Cook Medical, among others. The emerging market players include Biotronik, B. Braun SE, Biosensors International Group, Ltd., Elixir Medical, Alvimedica Group, and others.